![]() ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. (AMAG) carrying a Zacks Rank #1 (Strong Buy). A better-ranked stock in the health care sector is AMAG Pharmaceuticals, Inc. ![]() While Kite Pharma is a Zacks Rank #3 (Hold) stock, Amgen currently carries a Zacks Rank #2 (Buy). We note that CAR-T cell therapies have been attracting a lot of attention lately with pharmaceutical and biotech majors eyeing an entry into this therapeutic area.Īpart from Kite Pharma, Juno Therapeutics (JUNO) is also working on developing therapies utilizing CAR-T cell technology. With approval supplement on deck, Reata dives into launch of its first commercial. Amgen, which already has a strong presence in the oncology market, is in a position to use Kite Pharma’s proprietary technology in developing and expanding its immuno-oncology portfolio further. Amgen and Kite Pharma said today they will develop and commercialize what they termed the next generation of Chimeric Antigen Receptor (CAR) T cell immunotherapies, in a deal that could. Activist investor NexPoint threatens to block Parateks 462M sale. The company has a research collaboration and license agreement with Amgen Inc. In addition to this, Kite Pharma will be entitled to receive up to $525 million per Amgen’s program depending on the achievement of certain regulatory and commercialization milestones and tiered high single- to double-digit royalties on sales and payments for licensing Kite Pharma’s technology.Īmgen is also eligible to receive milestone payments of up to $525 million and tiered single-digit sales royalties per Kite Pharma’s program. The most accurate and popular Kite Pharmas email format is. As for the financial terms, Kite Pharma will receive an upfront payment of $60 million as well as R&D funding through the IND filing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |